NVP-TAE 226

TargetMol
Product Code: TAR-T1918
Supplier: TargetMol
CodeSizePrice
TAR-T1918-1mg1mg£103.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1918-2mg2mg£116.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1918-1mL1 mL * 10 mM (in DMSO)£153.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1918-5mg5mg£153.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1918-10mg10mg£204.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1918-25mg25mg£293.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1918-50mg50mg£389.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1918-100mg100mg£550.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
NVP-TAE226 is an effective FAK inhibitor (IC50: 5.5 nM) and most effective to Pyk2(IC50: 3.5 nM); 10- to 100-fold less effective against IGF-1R, InsR, c-Met, and ALK.
CAS:
761437-28-9
Formula:
C23H25ClN6O3
Molecular Weight:
468.94
Pathway:
Apoptosis; Cytoskeletal Signaling; Angiogenesis; Tyrosine Kinase/Adaptors
Purity:
0.9917
SMILES:
CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl
Target:
Apoptosis; FAK; c-Met/HGFR; PYK2; IGF-1R

References

1. Liu TJ, et al. Mol Cancer Ther, 2007, 6(4), 1357-1367. 2. Beierle EA, et al. Cancer Invest, 2008, 26(2), 145-151. 3. Schultze A, et al. Invest New Drugs, 2010, 28(6), 825-833. 4. Su Y, Li R, Ning X, et al. Discovery of 2, 4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities[J]. European Journal of Medicinal Chemistry. 2019 May 18;177:32-46.